PubMed HealthSearch

PubMed · 8610023

[Systemic mastocytosis: a case with diffuse bone involvement].

Abstract

The authors report the case of a 54-year-old woman with systemic mastocytosis with cutaneous, gastroenteric and skeletal involvement. The patient, who had presented wine-coloured skin lesions for years diagnosed as urticaria pigmentosa on the basis of the skin biopsy, was admitted to the Institute of Internal Medicine owing to the radiological findings of severe osteopenia. Instrumental and laboratory tests led to the correct diagnosis of type 1 systemic mastocytosis. The peculiarity of the case in question prompts the authors to recall the classification of mastocytosis, namely those pathological syndromes characterised by tissular infiltration by mast-cells, and to outline elements regarding its differential diagnosis in relation to disorders such as various forms of carcinoids and osteopenia, and in particular osteoporosis and osteolysis secondary to metastatic processes.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

V Biarese, P Raviolo, F Cesarani, L Lobetti. [Systemic mastocytosis: a case with diffuse bone involvement].. https://pubmed.ncbi.nlm.nih.gov/8610023/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The difficult breast.

Mammography is used to screen the population for breast cancer but often is inconclusive. There are several developing techniques to further assess the breast before biopsy that may decrease the number of benign biopsies. These include ultrasound, nuclear medicine, and MR imaging. When a biopsy is deemed necessary, there are several methods used to obtain tissue that are less invasive and less costly than open biopsy. This evolving area of breast evaluation is now filled with great expectation and uncertain future.

Biopsy

Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities.

CONTEXT: Postmenopausal vaginal bleeding is a common clinical problem. Endovaginal ultrasound (EVUS) is a noninvasive diagnostic test that may help determine which women should undergo endometrial biopsy. OBJECTIVE: To determine the accuracy of EVUS in detecting endometrial disease in postmenopausal women with vaginal bleeding according to hormone replacement use. DATA SOURCES: Literature search of English-language and non-English-language articles published from 1966 through November 1996 using MEDLINE and by a manual search of bibliographies of published articles. STUDY SELECTION: Studies were included if they prospectively collected EVUS measurements of endometrial thickness prior to obtaining endometrial tissue for histologic evaluation in postmenopausal women with vaginal bleeding. Of 85 studies that included data on EVUS and endometrial histology, 35 were included in the meta-analysis and included 5892 women. DATA EXTRACTION: Articles were reviewed and independently selected and abstracted by 2 reviewers. Disagreement was resolved by consensus. DATA SYNTHESIS: The overall summary mean weighted estimates of sensitivity and specificity were calculated for thresholds of endometrial thickness from 3 to 10 mm. Using a 5-mm threshold to define abnormal endometrial thickening, 96% (95% confidence interval [CI], 94%-98%) of women with cancer had an abnormal EVUS result, whereas 92% (95% CI, 90%-93%) of women with endometrial disease (cancer, polyp, or atypical hyperplasia) had an abnormal result. This did not vary by hormone replacement use. However, the number of women with normal histology who had an abnormal EVUS result did vary by hormone replacement use. In women who were not using hormone replacement therapy, 593 (8%) with normal histological findings had an abnormal EVUS result (specificity, 92%; 95% CI, 90%-94%), whereas 1544 (23%) using hormone replacement therapy had an abnormal EVUS result (specificity, 77%; 95% CI, 75%-79%). For a postmenopausal woman with vaginal bleeding with a 10% pretest probability of endometrial cancer, her probability of cancer is 1% following a normal EVUS result. CONCLUSION: Endovaginal ultrasound has a high sensitivity for detecting endometrial cancer and other endometrial disease and can reliably identify postmenopausal women with vaginal bleeding who are highly unlikely to have significant endometrial disease so that endometrial sampling may be unnecessary.

Biopsy